Forest Laboratories Inc. on Tuesday stated a quarterly profit, bolstered with higher sales of its flagship drugs for depression and Alzheimer's disease.
The drugmaker reported a fiscal fourth-quarter profit of $172.8 million, or 55 cents per share. That compared with a net loss of $237.9 million, or 75 cents per share, a year ago, when Forest took a big charge for an acquisition.
Results included a 35-cent per-share charge for a licensing payment.
Forest Laboratories is a pharmaceutical company headquartered in New York City, USA. Its revenues for the year ended 31 March 2007 were US$3.4 billion. The company's research & development spending has grown rapidly in recent years, and as of 2007, approached almost a billion US dollars a year, which put it on the list of the top 100 global corporations in R&D spending. Forest Laboratories is also known for licensing European pharmaceuticals for sale in the United States.
Satellite images of the naval base in Vilyuchinsk, Kamchatka, confirm that Russian nuclear submarines have left the base in turn